Results 261 to 270 of about 104,235 (402)

Primary (AL) Amyloidosis Following COVID‐19 Infection: A Case Report

open access: yesClinical Case Reports, Volume 14, Issue 2, February 2026.
ABSTRACT Primary (AL) amyloidosis is a rare systemic disorder caused by extracellular deposition of monoclonal immunoglobulin light chains, resulting in multi‐organ dysfunction. SARS‐CoV‐2 infection may induce persistent inflammatory and immune dysregulation, potentially promoting amyloid formation, although clinical evidence is limited, making the ...
Nasrin Gholami   +4 more
wiley   +1 more source

DUPILUMAB: A NEW ALLY FOR THE TREATMENT OF EOSINOPHILIC ESOPHAGITIS?

open access: hybrid
Lara Zaccarelli Rubira   +2 more
openalex   +2 more sources

Latent Variable Indirect Response Modeling of Cendakimab Exposure–Response for Longitudinal Dysphagia Days Using a Combined Uniform‐Binomial Likelihood Framework

open access: yesCPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 2, February 2026.
ABSTRACT To characterize the relationship between cendakimab exposure and the longitudinal efficacy endpoint dysphagia days (DD), E–R analyses were performed using data from the EE‐001 study (N = 427) with eosinophilic esophagitis. DD—a bounded, discrete endpoint assessed over 14‐day period via modified daily symptom diary (mDSD)—was modeled using a ...
Shengnan Du   +7 more
wiley   +1 more source

Central blood volume in cirrhosis [PDF]

open access: yes, 1993
Bendtsen, Flemming   +2 more
core   +1 more source

Home - About - Disclaimer - Privacy